Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide in ADPKD (DIPAK 1)
NCT01616927Phase 3Unknown
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2012
- Primary completion
- Aug 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of lanreotide in autosomal dominant polycystic kidney disease (ADPKD), sponsored by University Medical Center Groningen. Status: unknown.
02
Drugs
lanreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT01616927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01616927.